← Back to all trials
Recruiting
NCT05660811
Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure in Dialyzed Patients
Conditions: Atrial Fibrillation
Sex: All
Ages: 18 Years – N/A
Phase: PHASE4
Enrollment: 80
Sponsor: Institute of Cardiology, Warsaw, Poland
Location: Poland
Summary
SAFE-LAAC CKD Trial has been designed to gather data on the most optimal strategy of antiplatelet therapy after transcatheter left atrial appendage occlusion with Amplatzer or WATCHMAN device in patients with the end-stage renal disease treated with chronic haemodialysis or peritoneal dialysis
Eligibility Criteria
Inclusion Criteria:Successful left atrial appendage occlusion with Amplatzer or WATCHMAN device within 37 days prior to randomizationEnd-stage renal disease treated with chronic haemodialysis or peritoneal dialysisParticipant's age 18 years or older at the time of signing the informed consent formParticipant is willing to follow all study procedures; especially the randomized antiplatelet treatment regimenParticipant is willing to sign the study informed consent formExclusion Criteria:Indications to dual antiplatelet therapy other than left atrial appendage occlusion at the time of enrollment and/or predicted appearance of such indications within the duration of the trial (e.g.
planned coronary revascularization)Indications to anticoagulation at the time of enrollment and/or predicted appearance of such indications within the duration of the trial (e.g.
pulmonary embolism).
Does not apply to anticoagulation used during dialysisKnown allergy to clopidogrel and/or acetylsalicylic acid precluding its administration as specified by the protocolPeridevice leak >5mm on imaging study preceding enrollmentLeft atrial thrombus on an imaging study performed after successful left atrial appendage closure but before enrollmentLife expectancy of fewer than 18 monthsParticipation in other clinical studies with experimental therapies at the time of enrollment and/or preceding 3 monthsWomen who are pregnant or breastfeeding; women of childbearing potential who do not consent to apply at least two methods of contraception.
This criterion does not apply to women 2 years post menopause (with a negative pregnancy test 24 hours before randomization if <55 years old) or after surgical sterilization
Source: ClinicalTrials.gov (NCT05660811). StuddyBuddy aggregates publicly available trial information.